TRACON Pharmaceuticals (NYSE: TCON) — Company Overview, News & Financial Data
TRACON Pharmaceuticals develops targeted therapies for cancer and age-related macular degeneration, addressing unmet medical needs.
TRACON Pharmaceuticals
TRACON Pharmaceuticals (NASDAQ:TCON) is a biopharmaceutical company committed to the development and commercialization of targeted therapies for cancer and wet age-related macular degeneration. The company leverages its proprietary development platform to partner with and advance a diverse portfolio of therapeutic candidates, aiming to address unmet medical needs. TRACON's strategy involves collaborating with leading biopharmaceutical companies to efficiently progress its pipeline through clinical development stages. The company's objectives focus on bringing innovative treatment options to patients by harnessing its expertise in clinical trial management and regulatory processes. With a commitment to improving outcomes for patients facing serious conditions, TRACON Pharmaceuticals is dedicated to pioneering new pathways in therapeutic care.
Snapshot
Operations
Products and/or services of TRACON Pharmaceuticals
- Envafolimab, a novel single-domain antibody for the treatment of various solid tumors including soft tissue sarcoma.
- TJ004309, a CD73 antibody in development for oncology applications, targeting the adenosine pathway.
- Envafolimab in combination with Yervoy or Opdivo, a strategic approach targeting multiple cancers with potential synergistic effects.
- A collaborative project focused on developing bispecific antibodies, aiming to address unmet needs in oncology by targeting multiple pathways.
TRACON Pharmaceuticals executive team
- Mr. Craig R. Jalbert CIRACEO, President, Treasurer, Secretary & Director
- Dr. James L. Freddo M.D.Chief Medical Officer
- Mr. Ya HuangExecutive Director of Statistical Programming